Orforglipron vs Wegovy: Daily Pill vs Weekly Injection for Weight Loss

Orforglipron and Wegovy are both approved for chronic weight management, which makes “orforglipron vs Wegovy” a more direct comparison than orforglipron vs Ozempic (Ozempic’s approval centers on blood sugar control, not weight loss). Here’s how the two actually differ — molecule, route, dosing — without inventing a head-to-head efficacy number that doesn’t exist in a published trial.

What each one is

Orforglipron (brand Foundayo, Eli Lilly) is a once-daily oral GLP-1 receptor agonist — a small molecule, not a peptide. Per its FDA-approved label on DailyMed, it’s taken once daily with or without food, with no water restriction, and is approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity.

Wegovy (semaglutide, Novo Nordisk) is also a GLP-1 receptor agonist — same drug class, single-receptor mechanism — but it’s a peptide, delivered as a once-weekly subcutaneous injection. Per MedlinePlus, semaglutide injection is approved for chronic weight management under the Wegovy brand, and separately for type 2 diabetes blood sugar control under the Ozempic brand, at different doses.

Both drugs share the weight-management indication, which is why this comparison, unlike orforglipron vs Ozempic, is apples-to-apples on approved use. If you want the injectable-vs-diabetes-focused version of this comparison, see Orforglipron vs Ozempic.

How does orforglipron compare with Wegovy on dosing and route?

	Orforglipron (Foundayo)	Wegovy (semaglutide injection)
Molecule type	Small molecule	Peptide
Form / route	Oral tablet	Subcutaneous injection
Dosing frequency	Once daily	Once weekly
Food / water restrictions	None — with or without food, no water restriction	Not applicable (injected)
FDA-approved use	Chronic weight management	Chronic weight management
Common side effects	GI — nausea, vomiting, constipation, diarrhea	GI — nausea, vomiting, diarrhea, constipation

Sources: FOUNDAYO FDA label (DailyMed) and the MedlinePlus semaglutide injection page — both linked below.

The real difference: pill you swallow daily vs. injection once a week

Since both are approved for the same use, the practical decision usually comes down to administration, not indication:

• Orforglipron has no injection and no food/water timing rules. Per the FOUNDAYO label, it’s a tablet taken once daily, with or without food, no water restriction — no needle, no refrigeration logistics, no injection-site rotation.
• Wegovy is a once-weekly subcutaneous injection. That means fewer doses per month by count (about four vs. thirty), but each dose involves a needle, and the product typically needs to be stored and handled per its labeling. For people who dislike injections, or who travel frequently and want to avoid carrying injectable devices, a daily pill can be simpler logistically — for people who’d rather deal with something once a week instead of every day, the injection cuts down on how often they have to remember a dose.
• Semaglutide’s own oral form, Rybelsus, sits in between — daily like orforglipron, but with strict empty-stomach and water-timing rules that orforglipron doesn’t have, per MedlinePlus. See Orforglipron vs Rybelsus for that comparison specifically.

For a broader look at the oral-vs-injectable tradeoff across GLP-1s generally, see GLP-1 Pill vs Injection: What’s Actually Different.

Side effects: same class, similar pattern

Orforglipron and semaglutide (Wegovy) belong to the same drug class and share a similar side-effect profile. Per FDA and MedlinePlus drug information, the most common issues with GLP-1 receptor agonists are gastrointestinal — nausea, vomiting, diarrhea, and constipation — especially during dose increases. These tend to be dose-dependent and often ease over time, but individual experience varies. If nausea is a concern as you start either drug, Managing Orforglipron Nausea covers general strategies that apply broadly to GLP-1 side effects.

What this article won’t do: invent an efficacy comparison

There is no published head-to-head clinical trial directly comparing orforglipron to semaglutide (Wegovy) on weight-loss outcomes. Because of that, this article deliberately does not cite a “X% vs Y%” weight-loss comparison between them — that number doesn’t exist in a form that can be verified against a real trial, and inventing one would be misleading for a decision this consequential.

If you want efficacy figures, ask your prescriber. They can point you to each drug’s own trial data from its FDA approval studies and explain how the results might apply to your specific situation, rather than a comparison that hasn’t actually been run.

Bottom line

Orforglipron (Foundayo) and Wegovy (semaglutide) are both GLP-1 receptor agonists approved for chronic weight management, but they differ in molecule type (small molecule vs. peptide), route (daily oral tablet vs. weekly injection), and administration burden (no food/water rules vs. a weekly needle). Neither difference tells you which is more effective for you — that’s a question for a prescriber who can review the actual trial data behind each drug and factor in your health history, other conditions, and how you tolerate GLP-1 medications.

For more on orforglipron specifically, including dosing and titration, see Foundayo (Orforglipron): A Simple Guide.